Paradigm Pharmaceuticals is a drug repurposing company.
We take an existing approved drug, which has demonstrated safety in its approved indication/s and repurpose that drug in a new, patented therapeutic application. By following this approach, we achieve a reduction in the time, cost and risk associated with the clinical and commercial development pathway to taking new products to market.

Without doubt, some of medicine’s greatest opportunities have never come to light because they were consigned to the darkened corners of history before we had the technology or techniques to fully investigate them. Combining cutting edge science and unparalleled experience, Paradigm Biopharma is uniquely qualified to identify and liberate the true potential of under-utilised drugs and molecules to meet some of the world’s most significant unmet needs

Paradigm’s immediate commercial focus is the repurposing of Pentosan Polysulphate Sodium (PPS) for the treatment of Osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain and regeneration, PPS has genuine disease modifying potential.

In the presence of inflammation, the body can’t begin regenerating. We are targeting Osteoarthritis (OA) and other conditions with Pentosan Polysulfate Sodium (PPS) because it may address the complex biological responses to injury, infection or allergy which have short and long term components mediated by factors produced by immune cells.